Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inhibrx Biosciences Inc ( (INBX) ) just unveiled an announcement.
On October 23, 2025, Inhibrx Biosciences announced positive topline results from its ChonDRAgon study, showing that ozekibart significantly improved median progression-free survival in patients with advanced chondrosarcoma compared to placebo. This marks the first investigational therapy to demonstrate such benefits in this disease, which lacks approved systemic treatments. The company also reported promising interim data from expansion cohorts for colorectal cancer and Ewing sarcoma, indicating high response and disease control rates in heavily pretreated patients. Inhibrx plans to file a biologics license application with the FDA in the second quarter of 2026, potentially enhancing its positioning in the oncology market.
The most recent analyst rating on (INBX) stock is a Hold with a $38.00 price target. To see the full list of analyst forecasts on Inhibrx Biosciences Inc stock, see the INBX Stock Forecast page.
Spark’s Take on INBX Stock
According to Spark, TipRanks’ AI Analyst, INBX is a Neutral.
The overall stock score for Inhibrx Biosciences Inc is primarily influenced by its challenging financial performance, which is offset by positive technical indicators suggesting bullish momentum. However, the negative valuation metrics due to ongoing losses and lack of profitability weigh down the score.
To see Spark’s full report on INBX stock, click here.
More about Inhibrx Biosciences Inc
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates for oncology and rare diseases. The company utilizes advanced protein engineering platforms to address complex disease biology.
Average Trading Volume: 128,601
Technical Sentiment Signal: Buy
Current Market Cap: $543.5M
For an in-depth examination of INBX stock, go to TipRanks’ Overview page.